Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Authors	Year	Design	Country	Ethnicity	No. of case	No. of control	Genotyping methods	Matching criteria
Bouzgarrou et al[23]	2009	HCC	Tunisia	African	58	145	AS-PCR	Age, sex, geographical area
Ognjanovic et al[24]	2009	PCC	United States	Caucasian	120	230	Taqman	Age, sex, race
Tseng et al[25]	2006	HCC	Taiwan, China	Asian	208	528	PCR-RFLP	Race
Migita et al[26]	2005	HCC	Japan	Asian	48	188	PCR-SSP	-
Nieters et al[27]	2005	HCC	China	Asian	250	250	AS-PCR	Age, sex, race, district of residence
Heneghan et al[28]	2003	HCC	China	Asian	98	175	-	Age, sex
Shin et al[29]	2003	HCC	Korea	Asian	230	792	MAPA	-

HCC: Hospital-based case-control; PCC: Population-based case-control; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism; PCR-SSP: Polymerase chain reaction and sequence-specific primer typing; AS-PCR: Allele-specific polymerase chain reaction; MAPA: Multiplex automated primer extension analysis.

Table 2 Interleukin-10 gene polymorphism and hepatocellular carcinoma susceptibility

Gene	Polymorphism	HCC group genotype1			Control group genotype2			HWE	Ref.
		AA	AG	GG	AA	AG	GG
IL-10	-1082 G/A	39	79	-	67	147	-	Yes	[24]
IL-10	-1082 G/A	24	24	10	56	68	21	Yes	[23]
IL-10	-1082 G/A	42	5	1	176	10	2	No	[26]
IL-10	-1082 G/A	130	119	-	115	135	-	Yes	[27]
IL-10	-1082 G/A	86	12	0	160	15	0	Yes	[28]
IL-10	-1082 G/A	201	28	1	675	112	5	Yes	[29]
		AA	AC	CC	AA	AC	CC
IL-10	-592 C/A	93	84	31	259	223	46	Yes	[25]
IL-10	-592 C/A	17	23	8	85	78	25	Yes	[26]
IL-10	-592 C/A	89	101	26	384	299	65	Yes	[29]
IL-10	-592 C/A	49	38	11	95	60	19	Yes	[28]
		TT	TC	CC	TT	TC	CC
IL-10	-819 T/C	17	23	8	85	78	25	Yes	[26]
IL-10	-819 T/C	130	119	-	115	135	-	Yes	[27]
IL-10	-819 T/C	49	38	11	95	60	19	Yes	[28]

¹Absolute number of patients;

²Absolute number of controls; OR: Odds ratio; HCC: Hepatocellular carcinoma; HWE: Hardy-Weinberg equilibrium.

Table 3 Pooled odds ratio for Interleukin-10 gene polymorphism and hepatocellular carcinoma susceptibility in meta-analyses

Comparison	No. of study	OR (95% CI)	P-Publication bias			Heterogeneity test2
			P1value	Egger3	Begg4	P value	I2
IL-10-1082
AA vs AG + GG	6	1.11 (0.90, 1.37)	0.32	0.004	0.02	0.44	0
IL-10-592
CC vs AA + AC	4	1.68 (1.25, 2.26)	0.001	0.43	1	0.11	50.80%
C allele vs A allele	4	1.29 (1.12, 1.49)	0.001	0.51	0.73	0.86	0
IL-10-819
TT vs TC + CC	3	1.02 (0.79, 1.32)	0.88	0.13	0.3	0.14	48.90%

¹Fixed effects models were used, weighted by the inverse variance. All statistical tests are two sided;

²P < 0.1 is considered statistically significant for Q statistics; I² is interpreted as the proportion of total variation contributed by between-study variation;

³Egger’s test to evaluate publication bias, P < 0.05 is considered statistically significant;

⁴Begg’s test to evaluate publication bias, P < 0.05 is considered statistically significant. OR: Odds ratio.